Biophytis Announces Phase 2 Obesity Trial Strategy for BIO101

Biophytis ( (BPTSY) ) has provided an update.

On September 1, 2025, Biophytis S.A. announced a new Phase 2 clinical trial strategy for its lead candidate BIO101, targeting muscle wasting associated with obesity in Europe and Brazil. This trial aims to recruit 164 patients, with a strategic focus on rapid recruitment in Brazil and early regulatory engagement in Europe. The initiative underscores Biophytis’s ambition to expand BIO101’s potential into high-prevalence global indications, potentially positioning it as a first-in-class therapy in a multi-billion-euro market. The company is advancing towards trial initiation, with steps including regulatory approvals, site selection, and a diversified funding strategy.

Spark’s Take on BPTSY Stock

According to Spark, TipRanks’ AI Analyst, BPTSY is a Underperform.

Biophytis faces significant financial challenges, with ongoing losses and negative equity posing major risks. While there is some short-term technical strength, the long-term technical indicators and valuation metrics highlight weaknesses. The lack of substantial earnings call information increases uncertainty, contributing to a low overall score.

To see Spark’s full report on BPTSY stock, click here.

More about Biophytis

Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. Its lead drug candidate, BIO101, is a small molecule in development for muscular diseases like sarcopenia and metabolic disorders such as obesity. The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. Biophytis’s shares are listed on Euronext Growth Paris and its ADS on the OTC market.

Technical Sentiment Signal: Sell

Current Market Cap: $4.61M

Learn more about BPTSY stock on TipRanks’ Stock Analysis page.